Vericel (NASDAQ:VCEL) Releases Earnings Results, Beats Estimates By $0.21 EPS

Key Points

• Vericel beat third-quarter estimates: EPS was $0.27 versus $0.06 expected, while revenue rose 26.5% year over year to $85.37 million, above the $77.95 million consensus.
• The company raised its 2026 revenue outlook to $344 million–$346 million and adjusted EBITDA margin guidance to about 28%, citing strong results across its businesses.
• Growth was led by record MACI revenue of $67.4 million, up 21%, and record burn-care revenue of $18 million, up 52%; adjusted EBITDA increased 48% to $25.2 million.

Vericel (NASDAQ:VCEL - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.21, Zacks reports. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The firm had revenue of $85.37 million during the quarter, compared to analyst estimates of $77.95 million. During the same period last year, the firm posted $0.10 earnings per share. Vericel's revenue for the quarter was up 26.5% compared to the same quarter last year.

Here are the key takeaways from Vericel's conference call:

• Vericel reported third-quarter revenue of $85.4 million, up 26%, and raised 2026 revenue guidance to $344 million–$346 million after results exceeded expectations. The company also raised adjusted EBITDA margin guidance to approximately 28%.
• MACI revenue grew 21% to a record $67.4 million, with records for biopsies, implants, and participating surgeons; October also brought the strongest biopsy month since launch. Management cited sales-force expansion, deeper surgeon engagement, and MACI Arthro adoption as growth drivers, while noting that biopsies convert to procedures over time.
• Burn-care revenue reached a record $18 million, up 52%, with record quarterly revenue for both Epicel and commercial NexoBrid. Management attributed Epicel’s strength mainly to commercial execution, while acknowledging that burn-care results can be variable and that the number of severe burns is outside the company’s control.
• Profitability and cash generation strengthened: adjusted EBITDA rose 48% to $25.2 million, free cash flow was $16 million, and the company ended the quarter with $236 million in cash and investments and no debt. Vericel said it remains on track with its longer-term targets, while continuing investments in growth and exploring both share repurchases and business development.

Vericel Price Performance

Shares of VCEL traded up $6.30 during midday trading on Thursday, hitting $51.78. The stock had a trading volume of 2,682,362 shares, compared to its average volume of 594,165. Vericel has a 1 year low of $28.95 and a 1 year high of $55.60. The firm has a market cap of $2.65 billion, a PE ratio of 110.17 and a beta of 1.08. The stock's 50 day moving average is $40.56 and its 200 day moving average is $38.73.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Weiss Ratings reiterated a "hold (c)" rating on shares of Vericel in a research report on Thursday, October 29th. Canaccord Genuity Group set a $60.00 target price on shares of Vericel in a report on Thursday, July 30th. TD Cowen upped their target price on shares of Vericel from $55.00 to $58.00 and gave the company a "buy" rating in a research report on Friday, July 31st. HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Vericel in a research report on Tuesday, July 28th. Finally, Truist Financial reduced their price objective on Vericel from $58.00 to $52.00 and set a "buy" rating on the stock in a research note on Wednesday, October 14th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $57.20.

More Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Third-quarter revenue rose 26% year over year to $85.4 million, above analysts’ estimate of about $78 million. Earnings of $0.27 per share also topped the roughly $0.06 consensus, and net income increased 179% to $14.2 million. Reports highlighted record MACI sales as a key growth driver. Vericel Q3 2026 results and guidance
• Positive Sentiment: Vericel raised full-year 2026 revenue guidance to $344 million–$346 million, above the approximately $336 million analyst estimate, and lifted its adjusted EBITDA margin outlook to 28%. The higher forecast reinforces expectations for continued growth. Vericel raises 2026 revenue outlook
• Neutral Sentiment: The earnings call transcript may provide further detail on sales drivers and management’s outlook, but the headlines provided do not identify additional material developments. Vericel Q3 2026 earnings call transcript
• Negative Sentiment: A separate analysis argues that VCEL may look overvalued relative to its earnings support, a potential risk if investors question whether its recent growth and improved outlook justify the stock’s valuation. Valuation analysis of Vericel

About Vericel

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient's own cells or biologic materials to support tissue repair and healing.

Vericel's primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.